rmtОбщая реаниматологияGeneral Reanimatology1813-97792411-7110FSBI "SRIGR" RAMS10.15360/1813-9779-2019-5-106-126rmt-1821Research ArticleОБЗОРЫ И КРАТКИЕ СООБЩЕНИЯREVIEWS & SHORT COMMUNICATIONSРоль протеолитических систем стромы в опухолевой прогрессии (обзор)The Role of Stromal Proteolytic Systems in Cancer Progression (Review)КугаевскаяЕ. В.KugaevskayaE. V.

Россия, 119121, г. Москва, ул. Погодинская, д.10

10 Pogodinskaya Str., 119121 Moscow, Russia

ТимошенкоО. С.TimoshenkoO. S.

Россия, 119121, г. Москва, ул. Погодинская, д.10

10 Pogodinskaya Str., 119121 Moscow, Russia

ГурееваТ. А.GureevaT. A.

Россия, 119121, г. Москва, ул. Погодинская, д.10

10 Pogodinskaya Str., 119121 Moscow, Russia

СоловьеваН. И.SolovievaN. I.

Россия, 119121, г. Москва, ул. Погодинская, д.10

10 Pogodinskaya Str., 119121 Moscow, Russia

Nina.Solovyeva@ibmc.msk.ruНИИ биомедицинской химии им. В. Н. ОреховичаРоссияV. N. Orekhovich Research Institute of Biomedical ChemistryRussian Federation201908112019155106126Copyright © Кугаевская Е.В., Тимошенко О.С., Гуреева Т.А., Соловьева Н.И., 20192019Кугаевская Е.В., Тимошенко О.С., Гуреева Т.А., Соловьева Н.И.Kugaevskaya E.V., Timoshenko O.S., Gureeva T.A., Solovieva N.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.reanimatology.com/rmt/article/view/1821

Онкологические заболевания являются жизнеугрожающей патологией, занимающей второе место среди причин заболеваемости и смертности после сердечно-сосудистых заболеваний. Выяснение механизмов процесса канцерогенеза позволяет расширить арсенал средств для предупреждения развития критических состояний при этой патологии.В настоящее время протеолитические системы опухолевого микроокружения (ОМ) рассматриваются в качестве ключевых регуляторов процессов опухолевой прогрессии, обеспечивающих опухолевый рост, инвазию и метастазирование.В обзоре рассмотрены структура и роль ОМ в прогрессии опухоли. Приводятся современные данные о роли протеолитических систем во взаимодействии клеток стромы с клетками опухоли при различных типах рака человека.Наиболее изученными протеолитическими системами, вовлеченными в опухолевую прогрессию, являются система матриксных металлопротеиназ (ММП), системы активатора плазминогена урокиназного типа (uPA-система), а также различные катепсины, гранзимы и эластаза. Ингибирование внеклеточного протеолиза при развитии онкологического процесса рассматривается в качестве действенного подхода в терапии рака.

Oncological diseases belong to life-threatening pathologies being the second most frequent cause of morbidity and mortality after cardiovascular diseases. Clarification of carcinogenesis mechanisms makes it possible to expand the stock of tools available for prevention of critical illness accompanying this pathological condition.Nowadays, proteolytic systems of tumor microenvironment (ТМЕ) are regarded as key regulators of a tumor progression including tumor growth, invasion and metastazing. The review discusses ТМЕ structure and role in cancer progression.Recent data decipher the role of proteolytic systems in the interaction stromal cells with tumor cells in different types of cancer in humans. The most known proteolytic systems contributed to cancer progression are matrix metalloproteinase system (MMP), urokinase-type plasminogen activator system (uPA-system), various cathepsins, granzymes, and elastase. Inhibition of extracellular proteolysis in the course of an oncological process is considered an effective approach to cancer therapy.

канцерогенезопухолевое микроокружениестромаматриксные металлопротеиназыuPA-системапротеолизопухолевая прогрессияинвазияметастазированиеcarcinogenesistumor microenvironmentstromamatrix metalloproteinasesuPA-systemproteolysiscancer progressioninvasionmetastasisРабота выполнена в рамках Программы фундаментальных научных исследований государственных академий наук на 2013–2020 годы.ReferencesBussard K.M., Mutkus L., Stumpf K., Gomez-Manzano C., Marini F.C. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016; 18 (1): 84. DOI: 10.1186/s13058-016-0740-2. PMID: 27515302Bussard K.M., Mutkus L., Stumpf K., Gomez-Manzano C., Marini F.C. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016; 18 (1): 84. DOI: 10.1186/s13058-016-0740-2. PMID: 27515302Bougnaud S., Golebiewska A., Oudin A., Keunen O., Harter P.N., Mäder L., Azuaje F., Fritah S., Stieber D., Kaoma T., Vallar L., Brons N.H., Daubon T., Miletic H., Sundstrøm T., Herold-Mende C., Mittelbronn M., Bjerkvig R., Niclou S.P. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget. 2016; 7 (22): 31955–31971. DOI: 10.18632/oncotarget.7454. PMID: 27049916Bougnaud S., Golebiewska A., Oudin A., Keunen O., Harter P.N., Mäder L., Azuaje F., Fritah S., Stieber D., Kaoma T., Vallar L., Brons N.H., Daubon T., Miletic H., Sundstrøm T., Herold-Mende C., Mittelbronn M., Bjerkvig R., Niclou S.P. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget. 2016; 7 (22): 31955–31971. DOI: 10.18632/oncotarget.7454. PMID: 27049916Nilendu P., Sarode S.C., Jahagirdar D., Tandon I., Patil S., Sarode G.S., Pal J.K., Sharma N.K. Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell Oncol (Dordr). 2018; 41 (4): 353–367. DOI: 10.1007/s13402-018-0388-2. PMID: 30027403Nilendu P., Sarode S.C., Jahagirdar D., Tandon I., Patil S., Sarode G.S., Pal J.K., Sharma N.K. Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell Oncol (Dordr). 2018; 41 (4): 353–367. DOI: 10.1007/s13402-018-0388-2. PMID: 30027403Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646–674. DOI: 10.1016/j.cell.2011.02.013. PMID: 21376230Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646–674. DOI: 10.1016/j.cell.2011.02.013. PMID: 21376230Bhome R., Al Saihatia H.A., Goh R.W., Bullock M.D., Primrose J.N., Thomas G.J., Sayan A.E., Mirnezami A.H. Translational aspects in targeting the stromal tumor microenvironment: From bench to bedside. New Horiz. Transl. Med. 2016; 3 (1): 9–21. DOI: 10.1016/j.nhtm.2016.03.001. PMID: 27275004Bhome R., Al Saihatia H.A., Goh R.W., Bullock M.D., Primrose J.N., Thomas G.J., Sayan A.E., Mirnezami A.H. Translational aspects in targeting the stromal tumor microenvironment: From bench to bedside. New Horiz. Transl. Med. 2016; 3 (1): 9–21. DOI: 10.1016/j.nhtm.2016.03.001. PMID: 27275004Amend S. R., Pienta K. J. Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. Oncotarget. 2015; 6 (12): 9669–9678. DOI: 10.18632/oncotarget.3430. PMID: 25895024Amend S. R., Pienta K. J. Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. Oncotarget. 2015; 6 (12): 9669–9678. DOI: 10.18632/oncotarget.3430. PMID: 25895024Amend S. R., Roy S., Brown J. S., Pienta, K. J. Ecological paradigms to understand the dynamics of metastasis. Cancer Lett. 2016; 380 (1): 237–242. DOI: 10.1016/j.canlet.2015.10.005. PMID: 26458994Amend S. R., Roy S., Brown J. S., Pienta, K. J. Ecological paradigms to understand the dynamics of metastasis. Cancer Lett. 2016; 380 (1): 237–242. DOI: 10.1016/j.canlet.2015.10.005. PMID: 26458994Camacho D. F., Pienta K. J. Disrupting the networks of cancer. Clin. Cancer Res. 2012; 18 (10): 2801–2808. DOI: 10.1158/1078-0432.CCR-12-0366. PMID: 22442061Camacho D. F., Pienta K. J. Disrupting the networks of cancer. Clin. Cancer Res. 2012; 18 (10): 2801–2808. DOI: 10.1158/1078-0432.CCR-12-0366. PMID: 22442061de Groot A. E., Roy S., Brown J. S., Pienta K. J., Amend S. R. Revisiting seed and soil: examining the primary tumor and cancer cell foraging in metastasis. Mol. Cancer Res. 2017; 15 (4): 361–370. DOI: 10.1158/1541-7786.MCR-16-0436. PMID: 28209759de Groot A. E., Roy S., Brown J. S., Pienta K. J., Amend S. R. Revisiting seed and soil: examining the primary tumor and cancer cell foraging in metastasis. Mol. Cancer Res. 2017; 15 (4): 361–370. DOI: 10.1158/1541-7786.MCR-16-0436. PMID: 28209759Maley C. C., Aktipis A., Graham T.A., Sottoriva A., Boddy A.M., Janiszewska M., Silva A.S., Gerlinger M., Yuan Y., Pienta K.J., Anderson K.S., Gatenby R., Swanton C., Posada D., Wu C.I., Schiffman J.D., Hwang E.S., Polyak K., Anderson A.R.A., Brown J.S., Greaves M., Shibata D. Classifying the evolutionary and ecological features of neoplasms. Nat. Rev. Cancer 2017; 17 (10): 605–619. DOI: 10.1038/nrc.2017.69. PMID: 28912577Maley C. C., Aktipis A., Graham T.A., Sottoriva A., Boddy A.M., Janiszewska M., Silva A.S., Gerlinger M., Yuan Y., Pienta K.J., Anderson K.S., Gatenby R., Swanton C., Posada D., Wu C.I., Schiffman J.D., Hwang E.S., Polyak K., Anderson A.R.A., Brown J.S., Greaves M., Shibata D. Classifying the evolutionary and ecological features of neoplasms. Nat. Rev. Cancer 2017; 17 (10): 605–619. DOI: 10.1038/nrc.2017.69. PMID: 28912577Valkenburg K.C., Amber E. de Groot, Kenneth J. Pienta. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018; 15 (6): 366–381. DOI: 10.1038/s41571-018-0007-1. PMID: 29651130Valkenburg K.C., Amber E. de Groot, Kenneth J. Pienta. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018; 15 (6): 366–381. DOI: 10.1038/s41571-018-0007-1. PMID: 29651130Najafi M., Goradel N.H., Farhood B., Salehi E., Solhjoo S., Toolee H., Kharazinejad E., Mortezaee K. Tumor microenvironment: Interactions and therapy. J Cell Physiol. 2019; 234 (5): 5700–5721. DOI: 10.1002/jcp.27425. PMID: 30378106Najafi M., Goradel N.H., Farhood B., Salehi E., Solhjoo S., Toolee H., Kharazinejad E., Mortezaee K. Tumor microenvironment: Interactions and therapy. J Cell Physiol. 2019; 234 (5): 5700–5721. DOI: 10.1002/jcp.27425. PMID: 30378106Breznik B., Motaln H., Lah Turnšek T. Proteases and cytokines as mediators of interactions between cancer and stromal cells in tumours. Biol. Chem. 2017; 398 (7): 709–719. DOI: 10.1515/hsz-2016-0283. PMID: 28002021Breznik B., Motaln H., Lah Turnšek T. Proteases and cytokines as mediators of interactions between cancer and stromal cells in tumours. Biol. Chem. 2017; 398 (7): 709–719. DOI: 10.1515/hsz-2016-0283. PMID: 28002021Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010; 20 (3): 161–168. DOI: 10.1016/j.semcancer.2010.05.002. PMID: 20470890Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010; 20 (3): 161–168. DOI: 10.1016/j.semcancer.2010.05.002. PMID: 20470890Cun X., Li M., Wang S., Wang Y., Wang J., Lu Z., Yang R., Tang X., Zhang Z., He Q. A size switchable nanoplatform for targeting the tumor microenvironment and deep tumor penetration. Nanoscale. 2018; 10 (21): 9935–9948. DOI: 10.1039/c8nr00640g. PMID: 29770822Cun X., Li M., Wang S., Wang Y., Wang J., Lu Z., Yang R., Tang X., Zhang Z., He Q. A size switchable nanoplatform for targeting the tumor microenvironment and deep tumor penetration. Nanoscale. 2018; 10 (21): 9935–9948. DOI: 10.1039/c8nr00640g. PMID: 29770822Cammarota F., Laukkanen M.O. Mesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression. Stem Cells Int. 2016; 2016: 4824573. DOI: 10.1155/2016/4824573. PMID: 26798356Cammarota F., Laukkanen M.O. Mesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression. Stem Cells Int. 2016; 2016: 4824573. DOI: 10.1155/2016/4824573. PMID: 26798356Куликов В.А., Беляева Л.Е. Метаболическое перепрограммирование раковых клеток, Вестник ВГМУ 2013; 12 (2): 6–18.Kulikov V.A., Belyaeva L.E. Metabolic reprogramming of cancer cells. Vest. VGMU 2013; 12 (2): 6–18. [In Russ.]Boroughs L. K., DeBerardinis R. J. Metabolic pathways promoting cancer cell survival and growth. Nature Cell Biology. 2015; 17 (4): 351–359. DOI: 10.1038/ncb3124. PMID: 25774832Boroughs L. K., DeBerardinis R. J. Metabolic pathways promoting cancer cell survival and growth. Nature Cell Biology. 2015; 17 (4): 351–359. DOI: 10.1038/ncb3124. PMID: 25774832Muppalla J.N., Muddana K., Dorankula S.P., Thokala M.R., Pasupula A.P. Microenvironment-a role in tumour progression and prognosis. J Clin Diagn Res. 2013; 7 (9): 2096–2099. DOI: 10.7860/JCDR/2013/6619.3419. PMID: 24179956Muppalla J.N., Muddana K., Dorankula S.P., Thokala M.R., Pasupula A.P. Microenvironment-a role in tumour progression and prognosis. J Clin Diagn Res. 2013; 7 (9): 2096–2099. DOI: 10.7860/JCDR/2013/6619.3419. PMID: 24179956Antonio M.J., Le A. Different Tumor Microenvironments Lead to Different Metabolic Phenotypes. Adv Exp Med Biol. 2018; 1063: 119–129. DOI: 10.1007/978-3-319-77736-8_9. PMID: 29946782Antonio M.J., Le A. Different Tumor Microenvironments Lead to Different Metabolic Phenotypes. Adv Exp Med Biol. 2018; 1063: 119–129. DOI: 10.1007/978-3-319-77736-8_9. PMID: 29946782Kidd S., Spaeth E., Watson K., Burks J., Lu H., Klopp A., Andreeff M., Marini F.C. Origins of the tumor microenvironment: quantitative assessment of adiposederived and bone marrow-derived stroma. PLoS One. 2012; 7 (2): e30563. DOI: 10.1371/journal.pone.0030563. PMID: 22363446Kidd S., Spaeth E., Watson K., Burks J., Lu H., Klopp A., Andreeff M., Marini F.C. Origins of the tumor microenvironment: quantitative assessment of adiposederived and bone marrow-derived stroma. PLoS One. 2012; 7 (2): e30563. DOI: 10.1371/journal.pone.0030563. PMID: 22363446Xiong Y., McDonald L.T., Russell D.L., Kelly R.R., Wilson K.R., Mehrotra M., Soloff A.C., LaRue A.C. Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment. World J Stem Cells. 2015; 7 (2): 253–265. DOI: 10.4252/wjsc.v7.i2.253. PMID: 25815113Xiong Y., McDonald L.T., Russell D.L., Kelly R.R., Wilson K.R., Mehrotra M., Soloff A.C., LaRue A.C. Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment. World J Stem Cells. 2015; 7 (2): 253–265. DOI: 10.4252/wjsc.v7.i2.253. PMID: 25815113Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315: 1650–1659. DOI: 10.1056/NEJM198612253152606. PMID: 3537791Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315: 1650–1659. DOI: 10.1056/NEJM198612253152606. PMID: 3537791Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., Onder T.T., Wang Z.C., Richardson A.L., Weinberg R.A., Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumorpromoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010; 107 (46): 20009–20014. DOI: 10.1073/pnas.1013805107. PMID: 21041659Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., Onder T.T., Wang Z.C., Richardson A.L., Weinberg R.A., Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumorpromoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010; 107 (46): 20009–20014. DOI: 10.1073/pnas.1013805107. PMID: 21041659Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., Andreeff M., Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009; 4: e4992. DOI: 10.1371/journal.pone.0004992. PMID: 19352430Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., Andreeff M., Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009; 4: e4992. DOI: 10.1371/journal.pone.0004992. PMID: 19352430Medrek C., Ponten F., Jirstrom K., Leandersersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012; 12: 306. DOI: 10.1186/1471-2407-12-306. PMID: 22824040Medrek C., Ponten F., Jirstrom K., Leandersersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012; 12: 306. DOI: 10.1186/1471-2407-12-306. PMID: 22824040Smith H.A., Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med. 2013; 91 (4): 411–429. DOI: 10.1007/s00109-013-1021-5. PMID: 23515621Smith H.A., Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med. 2013; 91 (4): 411–429. DOI: 10.1007/s00109-013-1021-5. PMID: 23515621Brown J. M. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br. J. Radiol. 2014; 87 (1035): 20130686. DOI: 10.1259/bjr.20130686. PMID: 24338942Brown J. M. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br. J. Radiol. 2014; 87 (1035): 20130686. DOI: 10.1259/bjr.20130686. PMID: 24338942Hida K., Akiyama K., Ohga N., Maishi N., Hida Y. Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J. Biochem. 2013; 153 (3): 243–249. DOI: 10.1093/jb/mvs152. PMID: 23293323Hida K., Akiyama K., Ohga N., Maishi N., Hida Y. Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J. Biochem. 2013; 153 (3): 243–249. DOI: 10.1093/jb/mvs152. PMID: 23293323Kibria G., Hatakeyama H., Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch. Pharm. Res. 2014; 37 (1): 4–15. DOI: 10.1007/s12272-013-0276-2. PMID: 24272889Kibria G., Hatakeyama H., Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch. Pharm. Res. 2014; 37 (1): 4–15. DOI: 10.1007/s12272-013-0276-2. PMID: 24272889Ruffell B., Coussens L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015; 27 (4): 462–472. DOI: 10.1016/j.ccell.2015.02.015. PMID: 25858805Ruffell B., Coussens L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015; 27 (4): 462–472. DOI: 10.1016/j.ccell.2015.02.015. PMID: 25858805van Beijnum J. R., Nowak-Sliwinska P., Huijbers E. J., Thijssen V. L., Griffioen A. W. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol. Rev. 2015; 67 (2): 441–461. DOI: 10.1124/pr.114.010215. PMID: 25769965van Beijnum J. R., Nowak-Sliwinska P., Huijbers E. J., Thijssen V. L., Griffioen A. W. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol. Rev. 2015; 67 (2): 441–461. DOI: 10.1124/pr.114.010215. PMID: 25769965Choi J., Cha Y. J., Koo J. S. Adipocyte biology in breast cancer: from silent bystander to active facilitator. Prog. Lipid Res. 2017; 69: 11–20. DOI: 10.1016/j.plipres.2017.11.002. PMID: 29175445Choi J., Cha Y. J., Koo J. S. Adipocyte biology in breast cancer: from silent bystander to active facilitator. Prog. Lipid Res. 2017; 69: 11–20. DOI: 10.1016/j.plipres.2017.11.002. PMID: 29175445Kozin S. V., Kamoun W.S., Huang Y., Dawson M.R., Jain R.K., Duda D.G. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010; 70 (14): 5679–5685. DOI: 10.1158/0008-5472.CAN-09-4446. PMID: 20631066Kozin S. V., Kamoun W.S., Huang Y., Dawson M.R., Jain R.K., Duda D.G. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010; 70 (14): 5679–5685. DOI: 10.1158/0008-5472.CAN-09-4446. PMID: 20631066Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015; 5 (9): 915–919. DOI: 10.1158/2159-8290.CD-15-0563. PMID: 26272491Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015; 5 (9): 915–919. DOI: 10.1158/2159-8290.CD-15-0563. PMID: 26272491Roca H., Hernandez J., Weidner S., McEachin R.C., Fuller D., Sud S., Schumann T., Wilkinson J.E., Zaslavsky A., Li H., Maher C.A., Daignault-Newton S., Healy P.N., Pienta K.J. Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS ONE. 2013; 8 (10): e76773. DOI: 10.1371/journal.pone.0076773. PMID: 24124593Roca H., Hernandez J., Weidner S., McEachin R.C., Fuller D., Sud S., Schumann T., Wilkinson J.E., Zaslavsky A., Li H., Maher C.A., Daignault-Newton S., Healy P.N., Pienta K.J. Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS ONE. 2013; 8 (10): e76773. DOI: 10.1371/journal.pone.0076773. PMID: 24124593Jarvelainen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol. Rev. 2009; 61 (2): 198–223. DOI: 10.1124/pr.109.001289. PMID: 19549927Jarvelainen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol. Rev. 2009; 61 (2): 198–223. DOI: 10.1124/pr.109.001289. PMID: 19549927Mammoto T., Ingber D. E. Mechanical control of tissue and organ development. Development. 2010; 137 (9): 1407–1420. DOI: 10.1242/dev.024166. PMID: 20388652Mammoto T., Ingber D. E. Mechanical control of tissue and organ development. Development. 2010; 137 (9): 1407–1420. DOI: 10.1242/dev.024166. PMID: 20388652Hynes R. O., Naba A. Overview of the matrisome — an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 2012; 4 (1): a004903. DOI: 10.1101/cshperspect.a004903. PMID: 21937732Hynes R. O., Naba A. Overview of the matrisome — an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 2012; 4 (1): a004903. DOI: 10.1101/cshperspect.a004903. PMID: 21937732Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009; 9 (2): 108–122. DOI: 10.1038/nrc2544. PMID: 19165226Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009; 9 (2): 108–122. DOI: 10.1038/nrc2544. PMID: 19165226Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139 (5): 891–906. DOI: 10.1016/j.cell.2009.10.027. PMID: 19931152Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139 (5): 891–906. DOI: 10.1016/j.cell.2009.10.027. PMID: 19931152Mouw J. K., Yui Y., Damiano L., Bainer R.O., Lakins J.N., Acerbi I., Ou G., Wijekoon A.C., Levental K.R., Gilbert P.M., Hwang E.S., Chen Y.Y., Weaver V.M. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 2014; 20 (4): 360–367. DOI: 10.1038/nm.3497. PMID: 24633304Mouw J. K., Yui Y., Damiano L., Bainer R.O., Lakins J.N., Acerbi I., Ou G., Wijekoon A.C., Levental K.R., Gilbert P.M., Hwang E.S., Chen Y.Y., Weaver V.M. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 2014; 20 (4): 360-367. DOI: 10.1038/nm.3497. PMID: 24633304Kaukonen R., Mai A., Georgiadou M., Saari M., De Franceschi N., Betz T., Sihto H., Ventelä S., Elo L., Jokitalo E., Westermarck J., Kellokumpu-Lehtinen P.L., Joensuu H., Grenman R., Ivaska J. Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. Nat. Commun. 2016; 7: 12237. DOI: 10.1038/ncomms12237. PMID: 27488962Kaukonen R., Mai A., Georgiadou M., Saari M., De Franceschi N., Betz T., Sihto H., Ventelä S., Elo L., Jokitalo E., Westermarck J., Kellokumpu-Lehtinen P.L., Joensuu H., Grenman R., Ivaska J. Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. Nat. Commun. 2016; 7: 12237. DOI: 10.1038/ncomms12237. PMID: 27488962Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59 (19): 5002–5011. PMID: 10519415Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59 (19): 5002–5011. PMID: 10519415Turk B., Turk D., Salvesen G.S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des. 2002; 8 (18): 1623–1637. PMID: 12132995Turk B., Turk D., Salvesen G.S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des. 2002; 8 (18): 1623–1637. PMID: 12132995Hedrich J., Lottaz D., Meyer K., Yiallouros I., Jahnen-Dechent W., Stöcker W., Becker-Pauly C. Fetuin-A and Cystatin C Are Endogenous Inhibitors of Human Meprin Metalloproteases. Biochemistry. 2010; 49 (39): 8599–8607. DOI: 10.1021/bi1004238. PMID: 20806899Hedrich J., Lottaz D., Meyer K., Yiallouros I., Jahnen-Dechent W., Stöcker W., Becker-Pauly C. Fetuin-A and Cystatin C Are Endogenous Inhibitors of Human Meprin Metalloproteases. Biochemistry. 2010; 49 (39): 8599-8607. DOI: 10.1021/bi1004238. PMID: 20806899Wyganowska-Świątkowska M., Tarnowski M., Murtagh D., Skrzypczak-Jankun E., Jankun J. Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically. Int J Mol Med. 2019; 43 (1): 15–25. DOI: 10.3892/ijmm.2018.3983. PMID: 30431071Wyganowska-Świątkowska M., Tarnowski M., Murtagh D., Skrzypczak-Jankun E., Jankun J. Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically. Int J Mol Med. 2019; 43 (1): 15–25. DOI: 10.3892/ijmm.2018.3983. PMID: 30431071Pulz L.H., Strefezzi R.F. Proteases as prognostic markers in human and canine cancers. Vet Comp Oncol. 2017; 15 (3): 669–683. DOI: 10.1111/vco.12223. PMID: 27136601Pulz L.H., Strefezzi R.F. Proteases as prognostic markers in human and canine cancers. Vet Comp Oncol. 2017; 15 (3): 669–683. DOI: 10.1111/vco.12223. PMID: 27136601Verollet C., Charrière G.M., Labrousse A., Cougoule C., Le Cabec V., Maridonneau-Parini I. Extracellular proteolysis in macrophage migration: Losing grip for a breakthrough. Eur J Immunol. 2011; 41: 2805–2813. DOI: 10.1002/eji.201141538. PMID: 21953638Verollet C., Charrière G.M., Labrousse A., Cougoule C., Le Cabec V., Maridonneau-Parini I. Extracellular proteolysis in macrophage migration: Losing grip for a breakthrough. Eur J Immunol. 2011; 41: 2805–2813. DOI: 10.1002/eji.201141538. PMID: 21953638Roycik M.D., Fang X., Sang Q.X. A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates. Curr Pharm Des. 2009; 15 (12): 1295–1308. PMID: 19355969Roycik M.D., Fang X., Sang Q.X. A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates. Curr Pharm Des. 2009; 15 (12): 1295–1308. PMID: 19355969Christiaens V., Lijnen H.R. Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue. Arch Physiol Biochem. 2006; 112 (4–5): 254–259. DOI: 10.1080/13813450601093567. PMID: 17178599Christiaens V., Lijnen H.R. Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue. Arch Physiol Biochem. 2006; 112 (4–5): 254–259. DOI: 10.1080/13813450601093567. PMID: 17178599Riddick A.C., Shukla C.J., Pennington C.J., Bass R., Nuttall R.K., Hogan A., Sethia K.K., Ellis V., Collins A.T., Maitland N.J., Ball R.Y., Edwards D.R. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer. 2005; 92 (12): 2171–2180. DOI: 10.1038/sj.bjc.6602630. PMID: 15928670Riddick A.C., Shukla C.J., Pennington C.J., Bass R., Nuttall R.K., Hogan A., Sethia K.K., Ellis V., Collins A.T., Maitland N.J., Ball R.Y., Edwards D.R. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer. 2005; 92 (12): 2171–2180. DOI: 10.1038/sj.bjc.6602630. PMID: 15928670Eatemadi A., Aiyelabegan H.T., Negahdari B., Mazlomi M.A., Daraee H., Daraee N., Eatemadi R., Sadroddiny E. Role of protease and protease inhibitors in cancer pathogenesis and treatment. Biomed Pharmacother. 2017; 86: 221–231. DOI: 10.1016/j.biopha.2016.12.021.PMID: 28006747Eatemadi A., Aiyelabegan H.T., Negahdari B., Mazlomi M.A., Daraee H., Daraee N., Eatemadi R., Sadroddiny E. Role of protease and protease inhibitors in cancer pathogenesis and treatment. Biomed Pharmacother. 2017; 86: 221–231. DOI: 10.1016/j.biopha.2016.12.021. PMID: 28006747Liu W.L., Liu D., Cheng K., Liu Y.J., Xing S., Chi P.D., Liu X.H., Xue N., Lai Y.Z., Guo L., Zhang G. Evaluating the diagnostic and prognostic value of circulating cathepsin S in gastric cancer. Oncotarget. 2016; 7 (19): 28124–28138. DOI: 10.18632/oncotarget.8582. PMID: 27058412Liu W.L., Liu D., Cheng K., Liu Y.J., Xing S., Chi P.D., Liu X.H., Xue N., Lai Y.Z., Guo L., Zhang G. Evaluating the diagnostic and prognostic value of circulating cathepsin S in gastric cancer. Oncotarget. 2016; 7 (19): 28124–28138. DOI: 10.18632/oncotarget.8582. PMID: 27058412Pišlar A., Perišić Nanut M., Kos J. Lysosomal cysteine peptidases-Molecules signaling tumor cell death and survival. Semin Cancer Biol. 2015; 35: 168–179. DOI: 10.1016/j.semcancer.2015.08.001. PMID: 26255843Pišlar A., Perišić Nanut M., Kos J. Lysosomal cysteine peptidases-Molecules signaling tumor cell death and survival. Semin Cancer Biol. 2015; 35: 168–179. DOI: 10.1016/j.semcancer.2015.08.001. PMID: 26255843Wallin H., Abrahamson M., Ekstrom U. Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes. J Biol Chem. 2013; 288 (23): 17019–17029. DOI: 10.1074/jbc.M113.453449. PMID: 23629651Wallin H., Abrahamson M., Ekstrom U. Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes. J Biol Chem. 2013; 288 (23): 17019–17029. DOI: 10.1074/jbc.M113.453449. PMID: 23629651Mason S.D., Joyce J.A. Proteolytic networks in cancer. Trends Cell Biol. 2011; 21 (4): 228–237. DOI: 10.1016/j.tcb.2010.12.002. PMID: 25086747Mason S.D., Joyce J.A. Proteolytic networks in cancer. Trends Cell Biol. 2011; 21 (4): 228–237. DOI: 10.1016/j.tcb.2010.12.002. PMID: 25086747Jaiswal R.K., Varshney A. K., Yadava P.K. Diversity and functional evolution of the plasminogen activator system. Biomed Pharmacother. 2018; 98: 886–898. DOI: 10.1016/j.biopha.2018.01.029. PMID: 29571259Jaiswal R.K., Varshney A. K., Yadava P.K. Diversity and functional evolution of the plasminogen activator system. Biomed Pharmacother. 2018; 98: 886–898. DOI: 10.1016/j.biopha.2018.01.029. PMID: 29571259Кугаевская Е.В., Гуреева Т.А., Тимошенко О.С., Соловьева Н.И. Система активатора плазминогена урокиназного типа в норме и при жизнеугрожающих процессах (обзор). Общая реаниматология. 2018; 14 (6): 61–79. DOI: 10.15360/1813-9779-2018-6-61-79Kugaevskaya E.V., Gureeva T.A., Timoshenko O.S., Solovyeva N.I. Urokinase-Type Plasminogen Activator System in Norm and in Life-Threatening Processes (Review).Obschaya reaninatologiya= General Reanimatology. 2018; 14 (6): 61–79. [In Russ.] DOI: 0.15360/1813-9779-2018-6-61-79Mahmood N., Mihalcioiu C., Rabbani S.A. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol. 2018; 8: 24. DOI: 10.3389/fonc.2018.00024. PMID: 29484286Mahmood N., Mihalcioiu C., Rabbani S.A. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol. 2018; 8: 24. DOI: 10.3389/fonc.2018.00024. PMID: 29484286Binder B.R. Physiology and Pathophysiology of the Fibrinolytic System. Fibrinolysis. 1995; 9 (1): 3–8. DOI: 10.1016/S0268-9499(05)80002-5.Binder B.R. Physiology and Pathophysiology of the Fibrinolytic System. Fibrinolysis. 1995; 9 (1): 3–8. DOI: 10.1016/S0268-9499 (05)80002-5.Behrendt N., Ronne E., Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler. 1995; 376 (5): 269–279. PMID: 7662169Behrendt N., Ronne E., Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler. 1995; 376 (5): 269–279. PMID: 7662169Skrzydlewska E., Sulkowska M., Koda M., Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol. 2005; 11 (9): 1251–1266. DOI: 10.3748/wjg.v11.i9.1251. PMID: 15761961Skrzydlewska E., Sulkowska M., Koda M., Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol. 2005; 11 (9): 1251–1266. DOI: 10.3748/wjg.v11.i9.1251. PMID: 15761961Sotiropoulou G., Pampalakis G., Diamandis E.P. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009; 284 (48): 32989–32994. DOI: 10.1074/jbc.R109.027946. PMID: 19819870Sotiropoulou G., Pampalakis G., Diamandis E.P. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009; 284 (48): 32989–32994. DOI: 10.1074/jbc.R109.027946. PMID: 19819870Dass K., Ahmad A., Azmi A.S., Sarkar S.H., Sarkar F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008; 34 (2): 122–136. DOI: 10.1016/j.ctrv.2007.10.005. PMID: 18162327Dass K., Ahmad A., Azmi A.S., Sarkar S.H., Sarkar F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008; 34 (2): 122–136. DOI: 10.1016/j.ctrv.2007.10.005. PMID: 18162327Harris N.L.E., Vennin C., Conway J.R.W., Vine K.L., Pinese M., Cowley M.J.,Shearer R.F., Lucas M.C., Herrmann D., Allam A.H., Pajic M., Morton J.P.; Australian Pancreatic Cancer Genome Initiative, Biankin A.V., Ranson M.,Timpson P., Saunders D.N. SerpinB2 regulates stromal remodelling andlocal invasion in pancreatic cancer. Oncogene. 2017; 36 (30): 4288–4298. DOI: 10.1038/onc.2017.63. PMID: 28346421Harris N.L.E., Vennin C., Conway J.R.W., Vine K.L., Pinese M., Cowley M.J.,Shearer R.F., Lucas M.C., Herrmann D., Allam A.H., Pajic M., Morton J.P.; Australian Pancreatic Cancer Genome Initiative, Biankin A.V., Ranson M.,Timpson P., Saunders D.N. SerpinB2 regulates stromal remodelling andlocal invasion in pancreatic cancer. Oncogene. 2017; 36 (30): 4288–4298. DOI: 10.1038/onc.2017.63. PMID: 28346421Sato M., Kawana K., Adachi K., Fujimoto A., Yoshida M., Nakamura H., Nishida H., Inoue T., Taguchi A., Takahashi J., Kojima S., Yamashita A., Tomio K., Nagamatsu T., Wada-Hiraike O., Oda K., Osuga Y., Fujii T. Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. Int. J. Oncol. 2016; 48 (2): 829–835. DOI: 10.3892/ijo.2015.3283. PMID: 26676222Sato M., Kawana K., Adachi K., Fujimoto A., Yoshida M., Nakamura H., Nishida H., Inoue T., Taguchi A., Takahashi J., Kojima S., Yamashita A., Tomio K., Nagamatsu T., Wada-Hiraike O., Oda K., Osuga Y., Fujii T. Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. Int. J. Oncol. 2016; 48 (2): 829–835. DOI: 10.3892/ijo.2015.3283. PMID: 26676222Ellis V. In: Handbook of Proteolytic Enzymes, vol. 3 (Rawlings N.D., Salvesen G., eds.), Academic Press, 2013: 2938–2945.Ellis V. In: Handbook of Proteolytic Enzymes, vol. 3 (Rawlings N.D., Salvesen G., eds.), Academic Press, 2013: 2938–2945.Noh H., Hong S., Huang S. Role of urokinase receptor in tumor progression and development. Theranostics.2013; 3 (7): 487–495. DOI: 10.7150/thno.4218. PMID: 23843896.Noh H., Hong S., Huang S. Role of urokinase receptor in tumor progression and development. Theranostics.2013; 3 (7): 487–495. DOI: 10.7150/thno.4218. PMID: 23843896.Gonias S.L., Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front. Pharmacol. 2015; 6: 154. DOI: 10.3389/fphar.2015.00154. PMID: 26283964Gonias S.L., Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front. Pharmacol. 2015; 6: 154. DOI: 10.3389/fphar.2015.00154. PMID: 26283964Santibanez J.F., Obradović H., Kukolj T., Krstić J. Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition. Dev. Dyn. 2018; 247 (3): 382–395. DOI: 10.1002/dvdy.24554. PMID: 28722327Santibanez J.F., Obradović H., Kukolj T., Krstić J. Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition. Dev. Dyn. 2018; 247 (3): 382–395. DOI: 10.1002/dvdy.24554. PMID: 28722327Ulisse S., Baldini E., Sorrenti S., D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets. 2009; 9 (1): 32–71. DOI: 10.2174/156800909787314002. PMID: 19200050Ulisse S., Baldini E., Sorrenti S., D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets. 2009; 9 (1): 32–71. DOI: 10.2174/156800909787314002. PMID: 19200050Jo M., Lester R.D., Montel V., Eastman B., Takimoto S., Gonias S.L. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J. Biol. Chem. 2009; 284 (34): 22825–22833. DOI: 10.1074/jbc.M109.023960. PMID: 19546228Jo M., Lester R.D., Montel V., Eastman B., Takimoto S., Gonias S.L. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J. Biol. Chem. 2009; 284 (34): 22825–22833. DOI: 10.1074/jbc.M109.023960. PMID: 19546228Gilder A.S., Natali L., Van Dyk D.M., Zalfa C., Banki M.A., Pizzo D.P., Wang H., Klemke R.L., Mantuano E., Gonias S.L. The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurosphere. Sci. Rep. 2018; 8 (1): 2982. DOI: 10.1038/s41598-018-21358-1. PMID: 29445239Gilder A.S., Natali L., Van Dyk D.M., Zalfa C., Banki M.A., Pizzo D.P., Wang H., Klemke R.L., Mantuano E., Gonias S.L. The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurosphere. Sci. Rep. 2018; 8 (1): 2982. DOI: 10.1038/s41598-018-21358-1. PMID: 29445239Vandooren J., Opdenakker G., Loadman P.M., Edwards D.R. Proteases in cancer drug delivery. Adv. Drug. Deliv. Rev. 2016; 97: 144–155. DOI: 10.1016/j.addr.2015.12.020. PMID: 26756735Vandooren J., Opdenakker G., Loadman P.M., Edwards D.R. Proteases in cancer drug delivery. Adv. Drug. Deliv. Rev. 2016; 97: 144–155. DOI: 10.1016/j.addr.2015.12.020. PMID: 26756735Mekkawy A.H., Pourgholami M.H., Morris D.L. Involvement of urokinasetype plasminogen activator system in cancer: an overview. Med. Res. Rev. 2014; 34 (5): 918–956. DOI: 10.1002/med.21308. PMID: 24549574.Mekkawy A.H., Pourgholami M.H., Morris D.L. Involvement of urokinasetype plasminogen activator system in cancer: an overview. Med. Res. Rev. 2014; 34 (5): 918–956. DOI: 10.1002/med.21308. PMID: 24549574.Alizadeh H., Ma D., Berman M., Bellingham D., Comerford S.A., Gething M.J.H., Sambrook J.F., Niederkorn J.Y. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res. 1995; 14 (6): 449–458. PMID: 7671626Alizadeh H., Ma D., Berman M., Bellingham D., Comerford S.A., Gething M.J.H., Sambrook J.F., Niederkorn J.Y. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res. 1995; 14 (6): 449–458. PMID: 7671626Ma D., Gerard R.D., Li X-Y., Alizadeh H., Nierderkorn J.Y. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type-1 in an athymic mouse model. Blood. 1997; 90 (7): 2738–2746. PMID: 9326241Ma D., Gerard R.D., Li X-Y., Alizadeh H., Nierderkorn J.Y. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type-1 in an athymic mouse model. Blood. 1997; 90 (7): 2738–2746. PMID: 9326241Liu G., Shuman M.A., Cohen R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995; 60 (4): 501–506. PMID: 7829264Liu G., Shuman M.A., Cohen R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995; 60 (4): 501–506. PMID: 7829264Duffy M.J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies. Clin Chem. 2002; 48 (8): 1194–1197. PMID: 12142372Duffy M.J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies. Clin Chem. 2002; 48 (8): 1194–1197. PMID: 12142372Croucher D.R., Saunders D.N., Lobov S., Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer. 2008; 8 (7): 535–545. DOI: 10.1038/nrc2400. PMID: 18548086.Croucher D.R., Saunders D.N., Lobov S., Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer. 2008; 8 (7): 535–545. DOI: 10.1038/nrc2400. PMID: 18548086.Unkeless J., Dano K., Kellerman G.M., Reich E. Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator J. Biol. Chem. 1974; 249 (13): 4295–4305. PMID: 4368727.Unkeless J., Dano K., Kellerman G.M., Reich E. Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator J. Biol. Chem. 1974; 249 (13): 4295-4305. PMID: 4368727.Danø K., Reich E. Serine enzymes released by cultured neoplastic cells J. Exp. Med. 1978; 147 (3): 745–757. DOI: 10.1084/jem.147.3.745. PMID: 632749Danø K., Reich E. Serine enzymes released by cultured neoplastic cells J. Exp. Med. 1978; 147 (3): 745–757. DOI: 10.1084/jem.147.3.745. PMID: 632749Skriver L., L.I. Larsson, V. Kielberg, L.S. Nielsen, P.B. Andresen, P. Kristensen, K. Danø Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol. 1984; 99 (2): 753–757. DOI: 10.1083/jcb.99.2.753. PMID: 6378927Skriver L., L.I. Larsson, V. Kielberg, L.S. Nielsen, P.B. Andresen, P. Kristensen, K. Danø Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol. 1984; 99 (2): 753–757. DOI: 10.1083/jcb.99.2.753. PMID: 6378927Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas Am. J. Pathol. 1991; 138 (5): 1059–1067. PMID: 1850957Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas Am. J. Pathol. 1991; 138 (5): 1059–1067. PMID: 1850957Grøndahl-Hansen J., Ralfkiaer E., Kirkeby L.T., Kristensen P., Lund L.R., Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 1991; 138 (1): 111–117. PMID: 1702928Grøndahl-Hansen J., Ralfkiaer E., Kirkeby L.T., Kristensen P., Lund L.R., Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 1991; 138 (1): 111–117. PMID: 1702928Usher P.A., Thomsen O.F., Iversen P., Johnsen M., Brünner N., Høyer-Hansen G., Andreasen P., Danø K., Nielsen B.S. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int. J. Cancer. 2005; 113 (6): 870–880. DOI: 10.1002/ijc.20665. PMID: 15515049Usher P.A., Thomsen O.F., Iversen P., Johnsen M., Brünner N., Høyer-Hansen G., Andreasen P., Danø K., Nielsen B.S. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int. J. Cancer. 2005; 113 (6): 870–880. DOI: 10.1002/ijc.20665. PMID: 15515049Nielsen B.S., Sehested M., Timshel S., Pyke C., Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer Lab. Investig. J. Tech. Methods Pathol. 1996; 74 (1): 168–177. PMID: 8569179Nielsen B.S., Sehested M., Timshel S., Pyke C., Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer Lab. Investig. J. Tech. Methods Pathol. 1996; 74 (1): 168-177. PMID: 8569179Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., Johnsen M., Danø K. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab. Investig. J. Tech. Methods Pathol. 2001; 81 (11): 1485–1501. PMID: 11706057Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., Johnsen M., Danø K. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab. Investig. J. Tech. Methods Pathol. 2001; 81 (11): 1485–1501. PMID: 11706057Pyke C., Graem N., Ralfkiaer E., Rønne E., Høyer-Hansen G., Brünner N., Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma Cancer Res. 1993; 53 (8): 1911–1915. PMID: 8385573Pyke C., Graem N., Ralfkiaer E., Rønne E., Høyer-Hansen G., Brünner N., Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma Cancer Res. 1993; 53 (8): 1911–1915. PMID: 8385573Rømer J., Lund L.R., Eriksen J., Ralfkiaer E., Zeheb R., Gelehrter T.D., Danø K., Kristensen P. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J. Invest. Dermatol. 1991; 97 (5): 803–811. DOI: 10.1111/1523-1747.ep12486833. PMID: 1919045Rømer J., Lund L.R., Eriksen J., Ralfkiaer E., Zeheb R., Gelehrter T.D., Danø K., Kristensen P. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J. Invest. Dermatol. 1991; 97 (5): 803–811. DOI: 10.1111/1523-1747.ep12486833. PMID: 1919045Rømer J., Pyke C., Lund L.R., Ralfkiaer E., Danø K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin J. Invest. Dermatol. 2001; 116 (3): 353–358. DOI: 10.1046/j.1523-1747.2001.01241.x. PMID: 11231307Rømer J., Pyke C., Lund L.R., Ralfkiaer E., Danø K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin J. Invest. Dermatol. 2001; 116 (3): 353–358. DOI: 10.1046/j.1523-1747.2001.01241.x. PMID: 11231307Ciavarella S., Laurenzana A., De Summa S., Pilato B., Chillà A., Lacalamita R., Minoia C., Margheri F., Iacobazzi A., Rana A., Merchionne F., Fibbi G., Del Rosso M., Guarini A., Tommasi S., Serratì S. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer. 2017; 17 (1): 215. DOI: 10.1186/s12885-017-3183-y. PMID: 28340565Ciavarella S., Laurenzana A., De Summa S., Pilato B., Chillà A., Lacalamita R., Minoia C., Margheri F., Iacobazzi A., Rana A., Merchionne F., Fibbi G., Del Rosso M., Guarini A., Tommasi S., Serratì S. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer. 2017; 17 (1): 215. DOI: 10.1186/s12885-017-3183-y. PMID: 28340565Wang L., Madigan M.C., Chen H., Liu F., Patterson K.I., Beretov J., O’Brien P.M., Li Y. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol. Oncol. 2009; 114 (2): 265–272. DOI: 10.1016/j.ygyno.2009.04.031. PMID: 19450871Wang L., Madigan M.C., Chen H., Liu F., Patterson K.I., Beretov J., O’Brien P.M., Li Y. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol. Oncol. 2009; 114 (2): 265–272. DOI: 10.1016/j.ygyno.2009.04.031. PMID: 19450871Hildenbrand R., Schaaf A. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int. J. Oncol. 2009; 34 (1): 15–23. DOI: 10.3892/ijo_00000124. PMID: 19082473Hildenbrand R., Schaaf A. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int. J. Oncol. 2009; 34 (1): 15–23. DOI: 10.3892/ijo_00000124. PMID: 19082473Nielsen B.S., Rank F., Illemann M., Lund L.R., Danø K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int. J. Cancer. 2007; 120 (10): 2086–2095. DOI: 10.1002/ijc.22340. PMID: 17290405Nielsen B.S., Rank F., Illemann M., Lund L.R., Danø K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int. J. Cancer. 2007; 120 (10): 2086–2095. DOI: 10.1002/ijc.22340. PMID: 17290405Grøndahl-Hansen J., Christensen I.J., Rosenquist C., Brünner N., Mouridsen H.T., Danø K., Blichert-Toft M. High levels of urokinasetype plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53 (11): 2513–2521. DOI: PMID: 8388317Grøndahl-Hansen J., Christensen I.J., Rosenquist C., Brünner N., Mouridsen H.T., Danø K., Blichert-Toft M. High levels of urokinasetype plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53 (11): 2513–2521. DOI: PMID: 8388317Grøndahl-Hansen J., Peters H.A., van Putten W.L., Look M.P., Pappot H., Rønne E., Dano K., Klijn J.G., Brünner N., Foekens J.A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1995; 1 (10): 1079–1087. PMID: 9 815897Grøndahl-Hansen J., Peters H.A., van Putten W.L., Look M.P., Pappot H., Rønne E., Dano K., Klijn J.G., Brünner N., Foekens J.A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1995; 1 (10): 1079–1087. PMID: 9 815897Sameni M., Cavallo-Medved D., Franco O.E., Chalasani A., Ji K., Aggarwal N., Anbalagan A., Chen X., Mattingly R.R., Hayward S.W., Sloane B.F. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Res. 2017; 19 (1): 56. DOI: 10.1186/s13058-017-0847-0. PMID: 28506312 100.Mohamed M.M., Cavallo-Medved D., Rudy D., Anbalagan A., Moin K., Sloane B.F. Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell. Physiol. Biochem. 2010; 25 (2–3): 315–324. DOI: 10.1159/000276564. PMID: 20110692Sameni M., Cavallo-Medved D., Franco O.E., Chalasani A., Ji K., Aggarwal N., Anbalagan A., Chen X., Mattingly R.R., Hayward S.W., Sloane B.F. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Res. 2017; 19 (1): 56. DOI: 10.1186/s13058-017-0847-0. PMID: 28506312Daubriac J., Han S., Grahovac J., Smith E., Hosein A., Buchanan M.., Basik M., Boucher Y. The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1. Oncotarget. 2018; 9 (12): 10375–10387. DOI: 10.18632/oncotarget.23735. PMID: 29535813Mohamed M.M., Cavallo-Medved D., Rudy D., Anbalagan A., Moin K., Sloane B.F. Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell. Physiol. Biochem. 2010; 25 (2-3): 315–324. DOI: 10.1159/000276564. PMID: 20110692Mazar A.P., Ahn R.W., O’Halloran T.V. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr. Pharm. Des. 2011; 17 (19): 1970–1978. DOI: 10.2174/138161211796718152. PMID: 21711234Daubriac J., Han S., Grahovac J., Smith E., Hosein A., Buchanan M.., Basik M., Boucher Y. The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1. Oncotarget. 2018; 9 (12): 10375–10387. DOI: 10.18632/oncotarget.23735. PMID: 29535813Cianfrocca M.E., Kimmel K.A., Gallo J., Cardoso T., Brown M.M., Hudes G., Lewis N., Weiner L., Lam G.N., Brown S.C., Shaw D.E., Mazar A.P., Cohen R.B. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer. 2006; 94 (11): 1621. DOI: 10.1038/sj.bjc.6603171. PMID: 16705310Mazar A.P., Ahn R.W., O’Halloran T.V. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr. Pharm. Des. 2011; 17 (19): 1970–1978. DOI: 10.2174/138161211796718152. PMID: 21711234Ertongur S., Lang S., Mack B., Wosikowski K., Muehlenweg B., Gires O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int. J. Cancer. 2004; 110: 815–824. DOI: 10.1002/ijc.20192. PMID: 15170662Cianfrocca M.E., Kimmel K.A., Gallo J., Cardoso T., Brown M.M., Hudes G., Lewis N., Weiner L., Lam G.N., Brown S.C., Shaw D.E., Mazar A.P., Cohen R.B. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer. 2006; 94 (11): 1621. DOI: 10.1038/sj.bjc.6603171. PMID: 16705310Brungs D., Chen J., Aghmesheh M., Vine K.L., Becker T.M., Carolan M.G., Ranson M. The urokinase plasminogen activation system in gastroesophageal cancer: Asystematic review and meta-analysis. Oncotarget. 2017; 8, 23099–23109. DOI: 10.18632/oncotarget.15485. PMID: 28416743Ertongur S., Lang S., Mack B., Wosikowski K., Muehlenweg B., Gires O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int. J. Cancer. 2004; 110: 815–824. DOI: 10.1002/ijc.20192. PMID: 15170662Xu X., Cai Y., Wei Y., Donate F., Juarez J., Parry G., Chen L., Meehan E.J., Ahn R.W., Ugolkov A., Dubrovskyi O., O’Halloran T.V., Huang M., Mazar A.P. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). PLoS One. 2014; 9 (1): e85349. DOI: 10.1371/journal.pone.0085349. PMID: 24465541Brungs D., Chen J., Aghmesheh M., Vine K.L., Becker T.M., Carolan M.G., Ranson M. The urokinase plasminogen activation system in gastroesophageal cancer: Asystematic review and meta-analysis. Oncotarget. 2017; 8, 23099–23109. DOI: 10.18632/oncotarget.15485. PMID: 28416743Jabłońska-Trypuć A., Matejczyk M., Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J. Enzyme Inhib. Med. Chem. 2016; 31 (sup1): 177–183. DOI: 10.3109/14756366.2016.1161620. PMID: 27028474Xu X., Cai Y., Wei Y., Donate F., Juarez J., Parry G., Chen L., Meehan E.J., Ahn R.W., Ugolkov A., Dubrovskyi O., O’Halloran T.V., Huang M., Mazar A.P. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). PLoS One. 2014; 9 (1): e85349. DOI: 10.1371/journal.pone.0085349. PMID: 24465541Cui N., Hu M., Khalil R.A. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog. Mol. Biol. Transl. Sci. 2017; 147: 1–73. DOI: 10.1016/bs.pmbts.2017.02.005. PMID: 28413025Jabłońska-Trypuć A., Matejczyk M., Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J. Enzyme Inhib. Med. Chem. 2016; 31 (sup1): 177–183. DOI: 10.3109/14756366.2016.1161620. PMID: 27028474Liu J., Khalil R.A. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog. Mol. Biol. Transl. Sci. 2017; 148: 355–420. DOI: 10.1016/bs.pmbts.2017.04.003. PMID: 28662828Cui N., Hu M., Khalil R.A. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog. Mol. Biol. Transl. Sci. 2017; 147: 1–73. DOI: 10.1016/bs.pmbts.2017.02.005. PMID: 28413025Fisher K.E., Fei Q., Laird E.R., Stock J.L., Allen M.R., Sahagan B.G., Strick C.A. Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. Biochemistry. 2002; 41: 8289–8297. DOI: 10.1021/bi012076t. PMID: 12081477Liu J., Khalil R.A. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog. Mol. Biol. Transl. Sci. 2017; 148: 355–420. DOI: 10.1016/bs.pmbts.2017.04.003. PMID: 28662828Marchenko G.N., Ratnikov B.I., Rozanov D.V., Godzik A., Deryugina E.I., Strongin A.Y. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem. J. 2001; 356: 705–718. DOI: 10.1042/bj3560705. PMID: 11389678Fisher K.E., Fei Q., Laird E.R., Stock J.L., Allen M.R., Sahagan B.G., Strick C.A. Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. Biochemistry. 2002; 41: 8289–8297. DOI: 10.1021/bi012076t. PMID: 12081477Merchant N., Nagaraju G.P., Rajitha B., Lammata S., Jella K.K., Buchwald Z.S., Lakka S.S., Ali A.N. Matrix metalloproteinases: Their functional role in lung cancer. Carcinogenesis. 2017; 38: 766–780. DOI: 10.1093/carcin/bgx063. PMID: 28637319Marchenko G.N., Ratnikov B.I., Rozanov D.V., Godzik A., Deryugina E.I., Strongin A.Y. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem. J. 2001; 356: 705–718. DOI: 10.1042/bj3560705. PMID: 11389678Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., Tryggvason K. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. Science. 1999; 284: 1667–1670. DOI: 10.1126/science.284.5420.1667. PMID: 10356396Merchant N., Nagaraju G.P., Rajitha B., Lammata S., Jella K.K., Buchwald Z.S., Lakka S.S., Ali A.N. Matrix metalloproteinases: Their functional role in lung cancer. Carcinogenesis. 2017; 38: 766–780. DOI: 10.1093/carcin/bgx063. PMID: 28637319Yadav L., Puri N., Rastogi V., Satpute P., Ahmad R., Kaur G. Matrix metalloproteinases and cancer – roles in threat and therapy. Asian Pac. J. Cancer Prev. 2014; 15: 1085–1091. DOI: 10.7314/apjcp.2014.15.3.1085. PMID: 24606423Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., Tryggvason K. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. Science. 1999; 284: 1667–1670. DOI: 10.1126/science.284.5420.1667. PMID: 10356396Overall C.M., Kleifeld O. Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer. 2006; 6 (3): 227–239. DOI: 10.1038/nrc1821. PMID: 16498445Yadav L., Puri N., Rastogi V., Satpute P., Ahmad R., Kaur G. Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac. J. Cancer Prev. 2014; 15: 1085–1091. DOI: 10.7314/apjcp.2014.15.3.1085. PMID: 24606423Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007; 26 (8): 587–596. DOI: 10.1016/j.matbio.2007.07.001. PMID: 17669641Overall C.M., Kleifeld O. Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer. 2006; 6 (3): 227–239. DOI: 10.1038/nrc1821. PMID: 16498445Webb A.H., Gao B.T., Goldsmith Z.K., Irvine A.S., Saleh N., Lee R.P., Lendermon J.B., Bheemreddy R., Zhang Q., Brennan R.C., Johnson D., Steinle J.J., Wilson M.W., Morales-Tirado V.M. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017; 17: 434. DOI: 10.1186/s12885-017-3418-y. PMID: 28633655Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007; 26 (8): 587–596. DOI: 10.1016/j.matbio.2007.07.001. PMID: 17669641Eiro N., Fernandez-Gomez J., Sacristan R., Sacristán R., Fernandez-Garcia B., Lobo B., Gonzalez-Suarez J., Quintas A., Escaf S., Vizoso F.J. Stromal factors involved in human prostate cancer development, progression and castration resistance. J. Cancer Res. Clin. Oncol. 2017; 143: 351–359. DOI: 10.1007/s00432-016-2284-3. PMID: 27787597Webb A.H., Gao B.T., Goldsmith Z.K., Irvine A.S., Saleh N., Lee R.P., Lendermon J.B., Bheemreddy R., Zhang Q., Brennan R.C., Johnson D., Steinle J.J., Wilson M.W., Morales-Tirado V.M. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017; 17: 434. DOI: 10.1186/s12885-017-3418-y. PMID: 28633655Su S.C., Hsieh M.J., Yang W.E., Chung W.H., Reiter R.J., Yang S.F. Cancer metastasis: Mechanisms of inhibition by melatonin. J. Pineal. Research. 2017; 62 (1). DOI: 10.1111/jpi.12370. PMID: 27706852Eiro N., Fernandez-Gomez J., Sacristan R., Sacristán R., Fernandez-Garcia B., Lobo B., Gonzalez-Suarez J., Quintas A., Escaf S., Vizoso F.J. Stromal factors involved in human prostate cancer development, progression and castration resistance. J. Cancer Res. Clin. Oncol. 2017; 143: 351–359. DOI: 10.1007/s00432-016-2284-3. PMID: 27787597Solovуeva N.I., Timoshenko O.S., Gureeva T.A., Kugaevskaya E.V. Matrix metalloproteinases and their endogenous regulators in squamous cervical carcinoma (review of the own data). Biochem. Moscow Suppl. Ser. B. 2016; 10 (2): 110–121. DOI: 10.1134/S1990750816020116. PMID: 26716740Su S.C., Hsieh M.J., Yang W.E., Chung W.H., Reiter R.J., Yang S.F. Cancer metastasis: Mechanisms of inhibition by melatonin. J. Pineal. Research. 2017; 62 (1). DOI: 10.1111/jpi.12370. PMID: 27706852Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011; 278 (1): 16–27. DOI: 10.1111/j.1742-4658.2010.07919.x. PMID: 21087457Solovуeva N.I., Timoshenko O.S., Gureeva T.A., Kugaevskaya E.V. Matrix metalloproteinases and their endogenous regulators in squamous cervical carcinoma (review of the own data). Biochem. Moscow Suppl. Ser. B. 2016; 10 (2): 110–121. DOI: 10.1134/S1990750816020116. PMID: 26716740Stetler-Stevenson W.G. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008; 27 (1): 57–66. DOI: 10.1007/s10555-007-9105-8. PMID: 18058195Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011; 278 (1): 16–27. DOI: 10.1111/j.1742-4658.2010.07919.x. PMID: 21087457Birgisson H., Nielsen H.J., Christensen I.J., Glimelius B., Brünner N. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer. 2010; 46 (18): 3323–3331. DOI: 10.1016/j.ejca.2010.06.009. PMID: 20619633Stetler-Stevenson W.G. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008; 27 (1): 57–66. DOI: 10.1007/s10555-007-9105-8. PMID: 18058195Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2 (3): 161–174. DOI: 10.1038/nrc745. PMID: 11990853Birgisson H., Nielsen H.J., Christensen I.J., Glimelius B., Brünner N. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer. 2010; 46 (18): 3323–3331. DOI: 10.1016/j.ejca.2010.06.009. PMID: 20619633Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17: 463–516. DOI: 10.1146/annurev.cellbio.17.1.463. PMID: 11687497Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2 (3): 161–174. DOI: 10.1038/nrc745. PMID: 11990853Basset P., Bellocq J.P., Wolf C., Stoll I., Hutin P., Limacher J.M., Podhajcer O.L., Chenard M.P., Rio M.C., Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990; 348 (6303): 699–704. DOI: 10.1038/348699a0. PMID: 1701851Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17: 463–516. DOI: 10.1146/annurev.cellbio.17.1.463. PMID: 11687497Coussens L.M., Werb Z. Matrix metalloproteinases and the development of cancer Chem. Biol. 1996; 3 (11): 895–904. PMID: 8939708Basset P., Bellocq J.P., Wolf C., Stoll I., Hutin P., Limacher J.M., Podhajcer O.L., Chenard M.P., Rio M.C., Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990; 348 (6303): 699–704. DOI: 10.1038/348699a0. PMID: 1701851Qiao Y., Wan J., Zhou L., Ma W., Yang Y., Luo W., Yu Z., Wang H. Stimuliresponsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 11 (1): e1527. DOI: 10.1002/wnan.1527. PMID: 29726115Coussens L.M., Werb Z. Matrix metalloproteinases and the development of cancer Chem. Biol. 1996; 3 (11): 895–904. PMID: 8939708Kurschat P., Zigrino P., Nischt R., Breitkopf K., Steurer P., Klein CE, Krieg T., Mauch C.Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membranetype 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J. Biol. Chem. 1999; 274 (30): 21056–21062. DOI: 10.1074/jbc.274.30.21056. PMID: 10409657Qiao Y., Wan J., Zhou L., Ma W., Yang Y., Luo W., Yu Z., Wang H. Stimuliresponsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 11 (1): e1527. DOI: 10.1002/wnan.1527. PMID: 29726115Baumann P., Zigrino P., Mauch C., Breitkreutz D., Nischt R. Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes Br. J. Cancer. 2000; 83 (10): 1387–1393. DOI: 10.1054/bjoc.2000.1454. PMID: 11044366Kurschat P., Zigrino P., Nischt R., Breitkopf K., Steurer P., Klein CE, Krieg T., Mauch C.Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membranetype 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J. Biol. Chem. 1999; 274 (30): 21056–21062. DOI: 10.1074/jbc.274.30.21056. PMID: 10409657Kurschat P., Wickenhauser C., Groth W., Krieg T., Mauch C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography J. Pathol. 2002; 197 (2): 179–187. DOI: 10.1002/path.108. PMID: 12015741Baumann P., Zigrino P., Mauch C., Breitkreutz D., Nischt R. Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes Br. J. Cancer. 2000; 83 (10): 1387–1393. DOI: 10.1054/bjoc.2000.1454. PMID: 11044366Hofmann U.B., Westphal J.R., Zendman A.J., Becker J.C., D.J. Ruiter D.J., van Muijen G.N. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J. Pathol. 2000; 191 (3): 245–256. DOI: 10.1002/1096-9896 (2000)9999: 9999<::AID-PATH632>3.0.CO; 2-#. PMID: 10878545Kurschat P., Wickenhauser C., Groth W., Krieg T., Mauch C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J. Pathol. 2002; 197 (2): 179–187. DOI: 10.1002/path.108. PMID: 12015741Okada A., Bellocq J. P., Rouyer N., Chenard M. P., Rio M.C., Chambon P., Basset P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA. 1995; 92 (7): 2730–2734. DOI: 10.1073/pnas.92.7.2730. PMID: 7708715Hofmann U.B., Westphal J.R., Zendman A.J., Becker J.C., D.J. Ruiter D.J., van Muijen G.N. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J.Pathol. 2000; 191 (3): 245-256. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-# PMID: 10878545Airola K., Johansson N., Kariniemi A.L., Kahari V.M., Saarialho-Kere U.K. Human collagenase-3 is expressed in malignant squamous epithelium of the skin J. Invest. Dermatol. 1997; 109 (2): 225–231. PMID: 9242512Okada A., Bellocq J. P., Rouyer N., Chenard M. P., Rio M.C., Chambon P. and Basset P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA. 1995; 92 (7): 2730–2734. DOI: 10.1073/pnas.92.7.2730. PMID: 7708715Takahashi M., Fukami S., Iwata N., Inoue K., Itohara S., Itoh H., Haraoka J., Saido T. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacol. Res. 2002; 46 (2): 155–163. PMID: 12220955Airola K., Johansson N., Kariniemi A.L., Kahari V.M., Saarialho-Kere U.K. Human collagenase-3 is expressed in malignant squamous epithelium of the skin J. Invest. Dermatol. 1997; 109 (2): 225–231. PMID: 9242512Salvatore V., Teti G., Focaroli S., Mazzotti M.C., Mazzotti A., Falconi M. The tumor microenvironment promotes cancer progression and cell migration Oncotarget. 2017; 8 (6): 9608–9616. DOI: 10.18632/oncotarget.14155. PMID: 28030810Takahashi M., Fukami S., Iwata N., Inoue K., Itohara S., Itoh H., Haraoka J., Saido T. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacol. Res. 2002; 46 (2): 155–163. PMID: 12220955Littlepage L.E., Sternlicht M.D., Rougier N., Phillips J., Gallo E., Yu Y., Williams K., Brenot A., Gordon J.I., Werb Z. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res. 2010; 70 (6): 2224–2234. DOI: 10.1158/0008-5472.CAN-09-3515. PMID: 20215503Salvatore V., Teti G., Focaroli S., Mazzotti M.C., Mazzotti A., Falconi M. The tumor microenvironment promotes cancer progression and cell migration Oncotarget. 2017; 8 (6): 9608–9616. DOI: 10.18632/oncotarget.14155. PMID: 28030810Cid S., Eiro N., Fernández B., Sánchez R., Andicoechea A., Fernández-Muñiz P.I., González L.O., Vizoso F.J. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes. Clin Breast Cancer. 2018; 18 (1): e123–e133. DOI: 10.1016/j.clbc.2017.08.008. PMID: 28927692Littlepage L.E., Sternlicht M.D., Rougier N., Phillips J., Gallo E., Yu Y., Williams K., Brenot A., Gordon J.I., Werb Z. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res. 2010; 70 (6): 2224–2234. DOI: 10.1158/0008-5472.CAN-09-3515. PMID: 20215503Overall C.M., López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews Cancer. 2002; 2: 657–672. DOI: 10.1038/nrc884. PMID: 12209155Cid S., Eiro N., Fernández B., Sánchez R., Andicoechea A., Fernández-Muñiz P.I., González L.O., Vizoso F.J. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes. Clin Breast Cancer. 2018; 18 (1): e123–e133. DOI: 10.1016/j.clbc.2017.08.008. PMID: 28927692Ito T.K., Ishii G., Chiba H., Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene.2007; 26 (51): 7194–7203. DOI: 10.1038/sj.onc.1210535. PMID: 17525740Overall C.M., López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews Cancer. 2002; 2: 657–672. DOI: 10.1038/nrc884. PMID: 12209155Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol, 2000; 2 (10): 737–744. DOI: 10.1038/35036374. PMID: 11025665Ito T.K., Ishii G., Chiba H., Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene.2007; 26 (51): 7194–7203. DOI: 10.1038/sj.onc.1210535. PMID: 17525740Deryugina E.I., L. Soroceanu L., Strongin A.Y. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res. 2002; 62 (2): 580–588. PMID: 11809713Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol, 2000; 2 (10): 737–744. DOI: 10.1038/35036374. PMID: 11025665Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E.W., Foidart J.M., Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 2002; 16 (6): 555–564. DOI: 10.1096/fj.01-0790com. PMID: 11919158Deryugina E.I., L. Soroceanu L., Strongin A.Y. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res. 2002; 62 (2): 580–588. PMID: 11809713Hua F, A. DeClerck Y. Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials. Cancer Res. 2013; 73 (16): 4965–4977. DOI: 10.1158/0008-5472.CAN-13-0661. PMID: 23913938Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E.W., Foidart J.M., Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 2002; 16 (6): 555–564. DOI: 10.1096/fj.01-0790com. PMID: 11919158Olson O.C., Joyce J.A. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer. 2015; 15 (12): 712–729. DOI: 10.1038/nrc4027. PMID: 2659752Hua F, A. DeClerck Y. Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials. Cancer Res. 2013; 73 (16): 4965–4977. DOI: 10.1158/0008-5472.CAN-13-0661. PMID: 23913938Olson O.C., Joyce J.A. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer. 2015; 15 (12): 712–729. DOI: 10.1038/nrc4027. PMID: 2659752Olson O.C., Joyce J.A. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer. 2015; 15 (12): 712–729. DOI: 10.1038/nrc4027. PMID: 2659752

The authors declare that there are no conflicts of interest present.